Fluid Biopsy for the Diagnosis of Lung Cancer
Establishing a Diagnosis of Lung Cancer Through a Fluid Biopsy
Sponsor: National Cancer Institute (NCI)
Terminated
insufficient accrual
Other terminated trials from National Cancer Institute (NCI)
Other Lung Carcinoma trials with similar outcome
A observational or N/A phase clinical study on Lung Carcinoma, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 11 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Terminated
Status: Recruiting → Terminated
-
Sep 2024 — Oct 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2023 — Jul 2024 [monthly]
Recruiting
-
Sep 2022 — Jul 2023 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Dec 2021 — Sep 2022 [monthly]
Recruiting
-
May 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Apr 2020 — Nov 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Apr 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Southern California
For direct contact, visit the study record on ClinicalTrials.gov .